{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-094535","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.158989+00:00","generated_at":"2026-06-07T15:08:35.520977+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allarity Therapeutics terminates CEO James Cullem, appoints Thomas Jensen as CEO","bullets":["James Cullem terminated as CEO and all other positions on December 8, 2023.","Thomas Jensen appointed CEO effective December 8, 2023; previously SVP of Investor Relations and IT.","Jensen co-founded Allarity Therapeutics A/S in 2004 and leads the Denmark laboratories.","Audit committee entered consulting agreement with Dr. Jeremy R. Graff for R&D advisory on small molecule inhibitors.","No material plan or arrangement yet in place for new CEO's compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-094535","json":"https://secwatch.observer/filing/0001213900-23-094535.json","markdown":"https://secwatch.observer/filing/0001213900-23-094535.md","text":"https://secwatch.observer/filing/0001213900-23-094535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/ea189774-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:08:35.520977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"879d5da2d8","claim":"James Cullem was terminated as Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the “Company”) and all other positions with the Company and its subsidiaries.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e4b530f120","claim":"Thomas Jensen was appointed as Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company’s Board of Directors as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}